MediciNova, Inc. 10-Q Summary
Business context and reporting period
MediciNova is a development-stage biopharmaceutical company focused on therapeutics for serious diseases with unmet medical needs. Its principal programs are MN-166 (ibudilast) and MN-001 (tipelukast), with additional candidates MN-221 and MN-029. This unaudited Form 10-Q covers the three and nine months ended September 30, 2022; the filing was signed November 10, 2022. The company had 49,046,246 common shares outstanding as of November 8, 2022.
Financial performance and liquidity
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Revenue | $0.0 million, versus $37,500 | $0.0 million, versus $4.0 million |
| Research, development and patents expense | $2.5 million, versus $2.1 million | $7.1 million, versus $6.8 million |
| General and administrative expense | $1.4 million, versus $1.6 million | $4.3 million, versus $5.4 million |
| Operating loss | $(3.9) million, versus $(3.6) million | $(11.4) million, versus $(8.1) million |
| Net loss | $(3.7) million, or $(0.07) per share | $(11.1) million, or $(0.23) per share |
| Operating cash flow | Not separately provided for the quarter | $(8.9) million, versus $(5.7) million |
Revenue-based margins are not meaningful because the company reported no revenue in the 2022 periods. Research and development represented the primary operating investment. Interest income increased to $382,000 for the nine-month period from $107,000, reflecting higher cash and investment yields.
Cash and cash equivalents were $52.5 million at September 30, 2022, compared with $71.4 million at December 31, 2021. The company also held $10.0 million in bank certificates of deposit classified as investments. Working capital was $48.6 million. Total liabilities were $5.3 million, primarily current operating liabilities and lease obligations; the filing does not disclose outstanding funded debt. Total operating lease liabilities were $722,913.
Material changes versus the prior comparable period
- Nine-month revenue declined by $4.0 million because the company received two Genzyme-related clinical milestone payments in 2021 that did not recur in 2022.
- Nine-month net loss increased by $3.0 million, from $8.1 million to $11.1 million, primarily because of the absence of 2021 milestone revenue and higher research and development spending.
- Research and development expense increased by $370,000 for the nine-month period, driven mainly by higher MN-166 and MN-221 costs.
- General and administrative expense decreased by $1.1 million, primarily due to lower performance-based stock option expense.
- Cash used in investing activities increased to $10.0 million because the company purchased certificates of deposit. The comparable 2021 period had no investing cash outflow of this magnitude.
- Financing cash inflow was only $7,920 in the first nine months of 2022, compared with $20.7 million in 2021, when the company completed a private placement generating approximately $19.9 million net proceeds.
- Stock-based compensation decreased to $513,853 from $2.5 million in the comparable period.
Guidance, outlook, risks and unusual items
Management expects substantial net losses to continue for the next several years as product candidates are developed. The company expects research and development costs to increase through the remainder of 2022 as development programs progress.
Management stated that available cash and working capital are expected to fund operations at least through the end of 2023, but cautioned that resources may not fund all planned research and development programs. The company may seek additional capital, strategic partnerships, grants or other non-dilutive financing. An amended at-the-market facility permits up to $75.0 million of common-stock sales, but no shares were sold under the facility during the reported periods.
COVID-19 reduced patient visits at certain clinical sites, although management reported improved activity and continued clinical-trial enrollment. Management did not expect a material effect on development plans, timelines or liquidity but continues to monitor the risks.
The company announced top-line results in June 2022 for its completed MN-166 trial evaluating prevention of COVID-19-related acute respiratory distress syndrome. On October 24, 2022, after the quarter-end, the company finalized termination of its Kissei collaboration agreement and canceled the remaining MN-221 study.
Future potential milestone payments were estimated at $10.0 million for MN-166 and MN-001 and $33.5 million for other products. The timing of these payments cannot be estimated with certainty, and no minimum royalties are required under the disclosed license agreements. The principal risks include clinical-trial failure or delay, regulatory non-approval, inability to raise capital or generate revenue, dependence on third parties, intellectual-property disputes, product-liability exposure, competition, loss of key personnel and potential effects from COVID-19 and broader economic conditions. Management reported no material changes to previously disclosed risk factors and no material legal proceedings.
Facts investors should verify
- Whether the $52.5 million of cash and $10.0 million of certificates of deposit will support the planned development portfolio beyond management’s stated runway through the end of 2023.
- Clinical and regulatory progress, including results and follow-up actions for MN-166 and development milestones for MN-001.
- The company’s ability to secure partnerships, grants or additional equity financing without substantial dilution.
- The impact of the loss of recurring or milestone-based revenue on future operating cash burn.
- The terms and potential use of the $75.0 million ATM facility, including commissions of up to 3.5% of gross proceeds.
- The timing and likelihood of potential license milestone obligations totaling up to $43.5 million.
- Whether the termination of the Kissei agreement creates any additional payment, liability or development consequences after September 30, 2022.